Molecular Subtype
Chronic Myeloid Leukemia, BCR-ABL1 Positive
CI-CAN-00002365CMLExplore in graph →
Hematologic102 active trials3 approved drugs320 evidence items
- NCIt
- C3174
- OncoTree
- CMLBCRABL1
- DOID
- 0081088
- DOID
- 8552
Loading cancer entity…
Loading cancer entity…
Molecular Subtype
CI-CAN-00002365CMLExplore in graph →
Clinical trials
649 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (104)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07105319 | Ropeginterferon for Treatment Free Remission(ROPEG) | completed | Phase 4 | 65 | Dong-Wook KimOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT01735955 | Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study | completed | Phase 4 | 57 | Novartis PharmaceuticalsINDUSTRY | 16 | Feb 8, 2024 | clinicaltrials |
| NCT04155411 |
| Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP |
| unknown |
| Phase 4 |
| 65 |
| Shenzhen Second People's HospitalOTHER |
| 1 |
| Jul 27, 2022 |
| clinicaltrials |
| NCT02546674 | Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.(NILOdeepR) | completed | Phase 4 | 171 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 22, 2022 | clinicaltrials |
| NCT05367765 | A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase | not yet recruiting | Phase 4 | 2,400 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 10, 2022 | clinicaltrials |
| NCT05353205 | A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. | unknown | Phase 4 | 200 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 29, 2022 | clinicaltrials |
| NCT04677439 | Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure | unknown | Phase 4 | 200 | Shenzhen Second People's HospitalOTHER | 1 | Mar 16, 2022 | clinicaltrials |
| NCT01131325 | Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations(MACS1148) | terminated | Phase 4 | 3 | Novartis PharmaceuticalsINDUSTRY | 1 | May 20, 2021 | clinicaltrials |
| NCT01243489 | Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation(Crescendo) | completed | Phase 4 | 104 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbHOTHER | 1 | Dec 20, 2019 | clinicaltrials |
| NCT01578213 | Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients(ISAV) | completed | Phase 4 | 112 | University of Milano BicoccaOTHER | 5 | Dec 3, 2019 | clinicaltrials |
| NCT02204722 | A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients(IDEAL) | terminated | Phase 4 | 55 | Dong-A ST Co., Ltd.INDUSTRY | 1 | Jun 15, 2018 | clinicaltrials |
| NCT03332511 | Efficacy and Safety of Nilotinib in CML-CP(ENESTKorea) | completed | Phase 4 | 110 | Seoul National University HospitalOTHER | 0 | Nov 6, 2017 | clinicaltrials |
| NCT01605981 | Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase.(MACS1881) | withdrawn | Phase 4 | 0 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 20, 2017 | clinicaltrials |
| NCT02086487 | Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy(NISRI) | terminated | Phase 4 | 98 | King Abdullah International Medical Research CenterOTHER | 1 | Mar 7, 2017 | clinicaltrials |
| NCT01206088 | Tasigna in Glivec-resistant or Intolerant Patients in CML | completed | Phase 4 | 93 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 28, 2017 | clinicaltrials |
| NCT00786812 | Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase(MACS0439) | completed | Phase 4 | 89 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 23, 2017 | clinicaltrials |
| NCT01660906 | Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib | completed | Phase 4 | 39 | Bristol-Myers SquibbINDUSTRY | 5 | Nov 22, 2016 | clinicaltrials |
| NCT00845221 | Glivec in Pediatric Chronic Myeloid Leukemia (CML) | completed | Phase 4 | 44 | Poitiers University HospitalOTHER | 1 | Oct 11, 2016 | clinicaltrials |
| NCT02389920 | Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib | unknown | Phase 4 | 40 | Samsung Medical CenterOTHER | 0 | Mar 17, 2015 | clinicaltrials |
| NCT02317159 | Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia | unknown | Phase 4 | 90 | CttqINDUSTRY | 0 | Dec 15, 2014 | clinicaltrials |
| NCT00461929 | Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib(GIST) | terminated | Phase 4 | 68 | University Health Network, TorontoOTHER | 1 | Feb 13, 2009 | clinicaltrials |
| NCT00390897 | Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia | completed | Phase 4 | 360 | PETHEMA FoundationOTHER | 1 | Nov 27, 2008 | clinicaltrials |
Data updated 22 days agoSource updated Aug 22, 2025source: clinicaltrials